Introduction
Neuroblastoma is one of the most common solid tumors in children. However, its clinical behavior is enigmatic because the tumor usually regresses spontaneously when developed in patients under 1 year of age, but often grows rapidly to cause fatal outcomes when developed as an advanced tumor in patients over the age of 1 year (Brodeur, 2003; Schwab et al., 2003) . Recent nationwide mass screening (MS) in Japan for discovering neuroblastoma at the age of 6 months clearly demonstrated the presence of a large number of asymptomatic tumors undergoing spontaneous regression (Woods et al., 2002) , which had been suggested by Beckwith and Perrin (1963) . The involvement of TrkA, a high-affinity receptor for nerve growth factor, in the regression of neuroblastoma has been suggested; however, the molecular mechanisms of the regressive event still remain elusive (Nakagawara et al., 1993; Nakagawara, 1998) . On the other hand, the majority of sporadic neuroblastomas are discovered at advanced stages, and their prognosis is still very poor (Brodeur, 2003; Schwab et al., 2003) . Recently advanced cytogenetic analyses revealed that given subsets of neuroblastomas with a favorable prognosis possess the hyperdiploid karyotype of chromosomes (Look et al., 1984; Tomioka et al., 2003) and that the other subsets with an unfavorable prognosis usually possess the diploid or tetraploid karyotype and often have MYCN amplification, gains of chromosome arms 1q, 2p and 17q, as well as allelic losses of chromosome arms 1p, 3p and 11q (Brodeur, 2003; Schwab et al., 2003) . We and other investigators have previously reported the high accuracy of geneexpression profiling to predict the prognosis of neuroblastoma (Wei et al., 2004; Ohira et al., 2005) . However, the prognostic significance of genomic signatures when using a high-resolution DNA microarray in primary neuroblastomas has never been reported. Here, we applied microarray-based comparative genomic hybridization (array-CGH) to both sporadic and MSdetected neuroblastomas in order to comprehend their clinical behavior and found that genomic signatures, together with molecular signatures, stratified the novel risk groups in sporadic neuroblastomas.
Results

Patterns of genomic signatures in 236 primary neuroblastomas
The most prominent feature of 236 primary neuroblastomas (112 sporadic and 124 MS detected) was the apparent presence of three genomic groups (GGs) ( Figure 1a , its magnified, high-resolution figures are also indicated in Supplementary Figures S1a and b): the group of few chromosomal events (silent, GGS; n ¼ 29); the group of partial chromosomal gains/losses (GGP; n ¼ 77) and the group of whole chromosomal gains/ losses (GGW; n ¼ 130) (Supplementary Figures S2a and b) . Correlation analysis revealed that the global feature (see Materials and methods) was maximally correlated with the gain of the long arm of chromosome 17 (R ¼ À0.807) and with the gain of a whole chromosome 17 (R ¼ 0.75) (Supplementary Table S1a), therefore the genomic groups GGP and GGW were defined by the status of aberration, by 17q gain and 17 whole chromosomal gain occurred in chromosome 17, respectively. They were followed by DNA ploidy (R ¼ À0.642), loss of chromosome 1p (R ¼ À0.521), MYCN amplification (R ¼ À0.531), loss of chromosome 11q (R ¼ À0.5), low TrkA expression (R ¼ À0.47) and ageX1-year old (R ¼ À0.466). Even when tested in 112 sporadic tumors, the correlation coefficient was À0.773 in 17q gain, À0.705 in DNA ploidy, À0.598 in 1p loss, À0.565 in tumor stages, À0.502 in MYCN amplification, À0.49 in low TrkA expression and À0.458 in ageX 1-year old (Supplementary Table S1b ). These suggested that 17q gain was a characteristic and prognosis-related event in primary neuroblastomas. The percentages of DNA diploidy or tetraploidy were 83% (15/18), 66% (33/50) and 18% (17/94) in GGS, GGP and GGW tumors, respectively (Supplementary Table S2a) .
GGS tumors rarely showed chromosomal aberrations except MYCN amplification in 5 among 29 tumors (Figure 1b , a high-resolution figure is also indicated in Supplementary Figure S1c) . To date, the presence of the GGS subgroup with very silent aberrations of the tumor genome has never been verified definitely. The concern about the possible dilution of the tumor-cell DNA content by contamination of stromal cells was cleared by the detailed examination of GGS tumor specimens (see Supplementary Figure S2b and Supplementary Information).
Seventy-seven GGP tumors, which had 17q gain, were further subgrouped computationally according to the detailed chromosomal event, the presence and/or absence of 1p loss and 11q loss, which are characteristic and MYCN amplification (s, single copy of MYCN; a, MYCN amplification) (Figures 1a and b , and see Supplementary Information). GGP1 tumors were characterized by 1p loss and 17q gain as main aberrations. GGP1a (n ¼ 23) was one of the most common GGP tumors. They showed the diploid karyotype (10/13, 77%) and had MYCN amplification in addition to 1p loss and 17q gain. Interestingly, GGP1s tumors lacking MYCN amplification (n ¼ 6) showed relatively frequent 2p gain, as well as 14q loss, 1q gain, 4p loss and 7p gain that were rare in GGP1a tumors with MYCN amplification. GGP2 tumors were characterized by the presence of both 1p loss and 11q loss, in addition to 17q gain. In GGP2a, tumors with MYCN amplification (n ¼ 4) also frequently showed 1q gain. GGP3 tumors formed a group typically characterized by the presence of 11q loss and 17q gain without 1p loss. Intriguingly, only 1 of 27 GGP3 tumors had MYCN amplification. All GGP4 tumors except one, which presented neither 1p loss nor 11q loss, also had no MYCN amplification. The percentages of diploidy/tetraploidy in GGP1, GGP2, GGP3 and GGP4 tumors were 76% (13/17), 75% (6/8), 76% (13/17) and 13% (1/8), respectively (Supplementary Table S2a ).
GGW tumors with whole chromosomal gains and/or losses, especially with the predominant gain of whole chromosome 17 (Figure 1b) , were mostly the tumors detected by MS (94/130, 73%; see Supplementary Table  S2a ). The highest incidence of MS-detected neuroblastomas was observed in GGW4s tumors that were purely composed of whole chromosomal gains/losses. The DNA ploidy analysis revealed that 82% (77/94) of GGW tumors were hyperdiploidy. Similarly to GGP tumors, GGW tumors were categorized into tumors with the following aberrations: 1p loss (GGW1, n ¼ 5); both 1p loss and 11q loss (GGW2, n ¼ 2); 11q loss (GGW3, n ¼ 11) and without any one (GGW4, n ¼ 92). GGW5 tumors (n ¼ 20) formed a group of tumors with a low frequency of chromosome 17 on the BAC array. Like chromosome 17, chromosomes 6 and 7 were frequently gained in GGW tumors. MYCN amplification was observed in only three tumors belonging to GGW4 or GGW5 (3/112, 2.7%).
Genomic signatures and clinical outcomes
Genomic signatures of neuroblastomas unveiled previously unknown relationships between genetic subgroup and patient prognosis (Figure 1b) . The greatest surprise was the difference in the 5-year survival rates between the GGSa (0%, n ¼ 5) and GGSs (91%, n ¼ 24) subgroups (Po0.001). The other MYCN-amplified tumor subgroups, GGP1a (n ¼ 23), GGP2a (n ¼ 4) and GGWa (n ¼ 3), also showed very poor survival rates of 42, 0 and 0%, respectively. On the other hand, GGWs Risk stratification of neuroblastoma by microarray N Tomioka et al and GGP4s: 88%, n ¼ 9). Interestingly, in GGPs tumors, 1p loss (GGP1s, n ¼ 6) and 11q loss (GGP3s, n ¼ 26) seemed to have a similar effect on patient prognosis (5-year survival rates: 80 and 75%, respectively). However, GGP2s tumors with both 1p loss and 11q loss (n ¼ 7) had a poorer prognosis (57%) in an additive manner. Furthermore, the addition of 11q loss and 1q gain to MYCN amplification apparently afforded absolutely poor outcomes as suggested by the comparison between GGP1a (42%) and GGP2a tumors (0%). An analysis of 112 sporadic tumors also revealed a similar tendency except GGP1s, in which 2 sporadic tumors showed 0% survival, whereas all 4 MS-detected tumors gave good outcomes (Table 1 and Supplementary Figure S3 ). These suggested that MYCN amplification had the most powerful influence on clinical outcomes. We next compared the patterns of whole genome abnormalities of MYCN-amplified neuroblastomas between survivors (disease-free for more than 2 years after initiating treatment) and non-survivors (dead of disease). One of the most striking differences was frequent loss of 11q (Supplementary Figure S4) . Figure 2 shows the Kaplan-Meier cumulative survival curves in each genetic group. In sporadic neuroblastomas, the overall survival rates of GGW, GGS and GGP were 80% (n ¼ 36), 68% (n ¼ 23) and 43% (n ¼ 53), respectively ( Figure 2a ). The prognosis of GGP was significantly poorer than that of GGW (P ¼ 0.002). In MS-detected tumors, on the other hand, the survival rates of GGW, GGS and GGP were 100% (n ¼ 94), 100% (n ¼ 6) and 96% (n ¼ 24), respectively (no significant difference among the groups; Figure 2b ). The main difference between sporadic and MS-detected tumors was that the latter was detected before 1 year of age and had very few MYCN amplifications. Therefore, sporadic tumors were next subcategorized according (91) 100 (11) 100 (5) 88 (9) 75 (26) 57 (7) 0 (4) 80 (6) 42 (23) 91 ( Figure 3a shows that the 5-year survival rates of patients with GGSs (n ¼ 18), GGWs (n ¼ 33) and GGPs (n ¼ 25) tumors were 89, 85 and 53%, respectively, whereas those of patients with GGSa (n ¼ 5), GGWa (n ¼ 3) and GGPa (n ¼ 28) tumors involving MYCN amplification were 0, 33 and 34%, respectively (Figure 3b ). We then further examined the survival curves of patients with MYCN-nonamplified tumors in young (o1-year-old) and old (X1-year-old) patients. Figure 3c shows the 5-year survival rates of 88, 86 and 67% in GGWs (n ¼ 24), GGSs (n ¼ 7) and GGPs (n ¼ 3) tumors, respectively, among young patients, whereas they were 76, 91 and 51% in GGWs (n ¼ 9), GGSs (n ¼ 11) and GGPs (n ¼ 22) tumors, respectively, among old patients (Figure 3d ). The former pattern was similar to that in MS-detected tumors, which had high percentages of GGW tumors, whereas the latter contained high incidences of GGP tumors.
Effects of genomic signatures, MYCN amplification and age on prognosis in sporadic neuroblastomas
Segregation of the prognosis of sporadic neuroblastomas with a single copy of MYCN by genomic and molecular signatures Recently, we have generated a clinically useful cDNA microarray carrying 200 genes that predicts the prognosis of neuroblastomas with an accuracy rate of 89% (Ohira et al., 2005) . The univariate analysis of 112 sporadic neuroblastomas showed that both genomic signatures (GGP vs GGW þ GGS, P ¼ 0.003) and molecular signatures (posterior valueo0.5 vs X0.5, Po0.001) were highly significant prognostic indicators, like other variables including age (P ¼ 0.006), stage (Po0.001), tumor origin (P ¼ 0.001), TrkA expression (P ¼ 0.004), Shimada classification (Po0.001) and MYCN amplification (Po0.001; Table 2 ). In addition, genomic signature was a prognostic factor independent from molecular signature, age and tumor origin, although it showed no prognostic significance when stage, Shimada classification, or MYCN amplification was controlled (Table 2) . Even in sporadic neuroblastomas with a single copy of MYCN, the highest significance according to the univariate analysis was given to molecular signature (P ¼ 0.002), followed by tumor origin (P ¼ 0.006) and genomic signature (P ¼ 0.010; Table 2 ). The multivariate analysis also showed that genomic signature was a prognostic indicator independent from molecular signature or tumor origin (Table 2 ). As shown in Figure 4 , our inhouse expression microarrays segregated the survival curves of patients with sporadic tumors lacking MYCN amplification (GGSs þ GGPs þ GGWs) into the favorable (94%, n ¼ 17) and unfavorable (42%, n ¼ 13) prognosis groups (P ¼ 0.001). GGW3s  3  100  GGW4a  1  0  GGW4s  23  87  GGW5a  2  50  GGW5s  6  67 Abbreviations: GGP, partial chromosomal gains/losses genomic group; GGS, silent genomic group; GGW, whole gains and/or losses genomic group; OS, overall survival rate. Mass-screening detected neuroblastomas (n=124) Figure 2 Kaplan-Meier survival curves in three genomic groups (GGS, GGP and GGW) based on array-CGH. (a) Sporadic neuroblastomas: GGS vs GGP: P ¼ 0.109, GGS vs GGW: P ¼ 0.320 and GGP vs GGW: P ¼ 0.002. (b) Mass screening-detected neuroblastomas: GGS vs GGP: P ¼ 1.000, GGS vs GGW: P ¼ 1.000 and GGP vs GGW: P ¼ 1.000.
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Discussion
The present array-CGH analysis revealed the whole feature of the genomic abnormality patterns of sporadic and MS-detected neuroblastomas. The patterns of genomic aberrations in MS-detected neuroblastomas are similar to those in sporadic tumors, suggesting that they are genetically genuine neuroblastomas which are similar to sporadic tumors found in patients under 1 year of age. Indeed, both of them have a high tendency to regress spontaneously. The exceptions we found are that the incidence of GGPs tumors is relatively higher in MS-detected tumors than in sporadic tumors found among young patients and that their clinical outcome is very good. BAC array-based aCGH analyses have defined several minimal critical regions of gains and losses in 1p, 2p and 11q. These included minimal losses in 10 Mb regions of 1p36.3 (1pter to RP11-199O1, D1S244) and 11q23 (from RP11-42L18 to RP11-45N4). The 2 Mb region in 1p36.2-36.3 detected by a BAC clone RP11-219F4 (D1S507) exhibited highest deletion frequency of 32%. By combining the expression data obtained by the in-house microarrays harboring approximately 5340 genes derived from primary neuroblastomas, several candidate genes including CHD5 at 1p36 (Bagchi et al., 2007) as well as Survivin at 17q25 (Islam et al., 2000) were identified as lowly and highly expressed genes in neuroblastomas with advanced stages, respectively (manuscript in preparation). The amplicon surrounding the MYCN locus was ranged from 2.4 Mb proximal (G14110) to 5 Mb distal (D2S387) of MYCN itself and gains were further extended to wider range, from 2pter to 2p11.
To date, the presence of the GGS subgroup with very silent aberrations of the tumor genome has never been verified definitely. The distribution of GGS tumors is very unique; namely, they are present in both MS detected and sporadic tumors removed from the patients under 1 year of age. They are also found in tumors obtained from the patients over 1 year of age, and some of them possess MYCN amplification. Furthermore, GGS tumors mostly show diploid karyotype. These facts suggest that GGSs tumors might represent neuroblastoma at an early stage of carcinogenesis with early oncogenic hit(s), which later develop to GGP or Risk stratification of neuroblastoma by microarray N Tomioka et al GGW tumors. Since MS did not decrease the incidence of sporadic neuroblastomas (Brodeur et al., 2001; Levy, 2005) , GGSs tumors in young and old patients might be derived from different progenitor cells. It is interesting that the clinical outcome is very good for patients with MYCN-nonamplified GGSs tumors, whereas it is very bad for patients with GGSa tumors possessing MYCN amplification, implying again remarkable impact of MYCN amplification on the patient's outcome. The GGP group is characterized by the presence of 17q gain with other chromosomal abnormalities including MYCN amplification, 1p loss and 11q loss. Since this group of tumors shows multiple chromosomal aberrations with partial gains and/or losses, unknown causes to induce genomic instability might have triggered genesis of neuroblastoma in progenitor or stem cells of sympathetic cell lineage (Maris and Matthay, 1999; Nakagawara, 2004) . The frequently observed GGP tumors are as follows: GGP1a tumors with both 1p loss and MYCN amplification and GGP3s tumors with 11q loss but without MYCN amplification. The former may belong to a typical MYCN-amplified neuroblastoma (White et al., 1995) with a 5-year cumulative survival rate of 42% in our series, whereas the latter to the so-called intermediate type tumor (Srivatsan et al., 1993; Attiyeh et al., 2005) with the rate of 75%. In GGP tumors, it is obvious that MYCN amplification has the most powerful impact on the patient prognosis. Interestingly, among the GGPs tumors lacking MYCN amplification, 1p loss and 11q loss seem to similarly affect the prognosis. However, GGP2s tumors with both 1p loss and 11q loss show poorer prognosis in an additive manner. The similar additive effect has also been observed in GGP1a (42% Figure 4 Kaplan-Meier survival curves of sporadic neuroblastomas with a single copy of MYCN according to the molecular signature. Gene-expression profiling segregated patients into the favorable (posterior scoreX0.5) and unfavorable (posterior scoreo0.5) prognosis groups (P ¼ 0.001). The posterior score denotes how likely the patient would show good outcome after 5 years (Ohira et al., 2005) .
Risk stratification of neuroblastoma by microarray N Tomioka et al survival) and GGP2a (0% survival) with MYCNamplified tumors. These suggest that 1p loss and 11q loss may independently affect the outcomes of neuroblastoma. Interestingly, one of the main characteristics of the MYCN-amplified tumors found in the long-term survivors is a lack of 11q loss (Supplementary Figure  S4) , corresponding to the observation that the high percentage of 5-year survival rate is shown in the GGP1a group with 1p loss but without 11q loss.
GGW neuroblastoma has a favorable prognosis, as reported (Vandesompele et al., 1998) . Since the pattern of chromosomal aberrations is represented by whole chromosomal gains and/or losses, mitotic dysfunction during the cell division cycle in progenitor or stem cells might have generated neuroblastoma (Maris and Matthay, 1999; Nakagawara, 2004) . Interestingly, 1p loss or 11q loss in a minor population of GGWs tumors (GGW1s and GGW3s) seems not to affect the prognosis.
The presence of different patterns of genomic aberrations like GGS, GGP and GGW may reflect differences in stem or progenitor cells targeted to generate different genetic subsets of neuroblastomas. Although carcinogenic events to cause neuroblastomas may occur sequentially (Tonini, 1993) , our serial analyses of six paired primary and recurrent tumors interestingly suggest that the major genetic events, for example, MYCN amplification, 1p loss, 11q loss and 17q gain, could occur not always in order during tumor progression (Supplementary Table S3) .
Thus, the genomic signatures presented here successfully categorized new prognostic subgroups of neuroblastomas. The rather consistent patterns of genomic abnormalities provide reliable information to understanding of the genetic bases which underlie the clinical phenotypes of neuroblastomas with different survival rates. However, the pattern of genomic abnormalities may often lack biological significance affecting the clinical behavior of individual tumors. The geneexpression profile well reflects the biology of individual tumor. Therefore, establishment of the combined system of both genomic and molecular signatures is ideal for predicting the prognosis of individual patients with neuroblastoma. The present study has clearly shown that genomic and molecular signatures are independent prognostic indicators and suggests that an expression microarray could compensate for the relevant lack when used only genomic signature. In conclusion, combined genomic and molecular signatures may be clinically useful for constituting an ideal system to categorize and even individualize each tumor, which may make tailored medicine of neuroblastoma possible.
Materials and methods
Patients, tissue specimens and DNA/RNA resources Tumor specimens were collected from 236 patients who had undergone biopsy or surgery at various institutions in Japan (see Supplementary Information). They included 112 sporadic and 124 MS-detected neuroblastoma specimens. All tumors were histopathologically diagnosed as neuroblastoma or ganglioneuroblastoma and were staged according to the International Neuroblastoma Staging System . Informed consent was obtained at each institution or hospital. The procedure of this study was approved by the Institutional Review Board of the Chiba Cancer Center (CCC7817). Patients were treated by the standard protocols (Kaneko et al., 2002; Iehara et al., 2006) in Japan between 1995 and 2003. All MS-detected tumors were diagnosed between 6 and 8 months after birth by measuring urinary catecholamine metabolites in Japan (Sawada et al., 1984) . Fresh neuroblastoma tissues removed during surgery were stored at À801C. MYCN copy number, TrkA mRNA expression and DNA ploidy were measured as reported previously (Islam et al., 2000) .
Microarray-based comparative genomic hybridization A chip carrying 2464 BAC clones prepared by ligationmediated PCR, which covers the whole human genome at roughly 1.2-Mb resolution (Snijders et al., 2001; Albertson et al., 2003) , was used. The 500-ng aliquots of tumors and reference DNAs were labeled by random priming with each Cy3-dCTP and Cy5-dCTP (Amersham Pharmacia, Piscataway, NJ, USA). Hybridization was performed as previously reported (Pinkel et al., 1998) . UCSF Spot and UCSF Sproc programs to analyse values for spotted clones (Jain et al., 2002) were used. All array-CGH data are available at NCBI Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE 5784.
cDNA microarrays
In-house cDNA microarrays, carrying 5340 cDNAs obtained from the oligo-capping cDNA libraries generated from anonymous neuroblastoma tissues (Ohira et al., , 2005 , were used. Preparation of RNA, hybridization, reading of spots and statistical analyses were conducted as reported previously (Ohira et al., 2005) . Gene-expression profile data described in this study is available at NCBI GEO with accession number GSE 5779.
Statistical analysis
The fluorescence ratio for each array CGH spot was normalized and rescaled into estimated copy number aberrations of each clone according to the comb-fit method (Oba et al., 2006;  see also Supplementary Figure S2a) . Chromosomal events were detected by locally smoothing variations in copy number aberrations of clones on a chromosome and by applying threshold rules (see Supplementary Figure S2a and Supplementary Information for more detail). The numbers of whole chromosomal events, Nw and of partial chromosomal events, Np, were counted for 22 þ 2 chromosomes in every specimen, and the scatter plot in the Nw-Np plane exhibited apparent three clusters: whole differential dominant (Nw>Np), partial differential dominant (NwoNp) and silent (NwE0, NpE0) (Supplementary Figure S2b) . To discriminate whole differential dominant from partial differential dominant, we defined a 'global' feature variable a as computationally evaluated as the ratio between Nw and Np; when a was small (large), the sample was likely to be whole (partial) differential dominant (see Supplementary Information for more detail) . A differential analysis of gene expression was made using standard t-test with the q-value analysis (Storey and Tibshirani, 2003) for incorporating a false discovery rate (to deal with multiple statistical tests). A survival analysis was made based on Kaplan-Meier and log-rank tests. Univariate and multivariate analyses were made according to the Cox hazard models.
